定量乙肝表面抗原结合乙型肝炎e抗原在延长治疗聚乙二醇干

StephenW

J Clin Virol. 2015 Oct 9;72:88-94. doi: 10.1016/j.jcv.2015.09.012. [Epub ahead of print]
Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.Chen J1, Zhang DH1, Xu CR2, Zhu MY1, Yang ZT1, Gong QM1, Yu DM3, Zhang XX4.
Author information

• 1Research Unit of Clinical Virology, Institute of Infectious and Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China.
• 2Department of Infection Diseases, Southeast Hospital, Xiamen University, Zhangzhou 363000, People's Republic of China.
• 3Research Unit of Clinical Virology, Institute of Infectious and Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China. Electronic address: [email protected].
• 4Research Unit of Clinical Virology, Institute of Infectious and Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China; Translational Medicine Research Center, Ruijin Hospital North, Shanghai Jiaotong University School of Medicine, Shanghai 200025, People's Republic of China. Electronic address: [email protected].
  

AbstractBACKGROUND: The best strategy for chronic hepatitis B patients with poor response to 48 weeks of Peginterferon-based therapy has been controversial and the predictive value of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and hepatitis B virus (HBV) DNA levels for determining the sustained virological response (SVR) of these patients is uncertain.
OBJECTIVES: To optimize management of these patients and evaluate the use of these serobiomarkers to predict SVR.
STUDY DESIGN: Eighty-one patients with an unsatisfactory response after 48 weeks of Peginterferon-based therapy were treated with extended Peginterferon therapy with or without nucleo(s) tide analogues (NAs), for a total of 96 weeks of Peginterferon treatment. HBsAg, HBeAg and HBV DNA levels were measured serially during the treatment and follow-up.
RESULTS AND CONCLUSIONS: Twenty-six of 81 patients (32.1%) attained SVR during the 72-week follow-up. The SVR rate was not statistically different between groups receiving 1-year prolongation of Peginterferon with or without NAs. The serum HBsAg cut-off of 1800IU/mL at week 48 had area under curve (AUC) of 0.727, and the serum HBsAg cut-off of 1500IU/mL, combined with HBeAg loss at week 72, had AUC of 0.753 to predict SVR during the follow-up. In conclusion, extended treatment with Peginterferon with or without NAs for patients with unsatisfactory response after 48 weeks of Peginterferon-based therapy is a promising strategy to achieve SVR, and quantitative serum HBsAg at week 48 and HBsAg level combined with HBeAg loss at week 72 of therapy can predict SVR to prolongation therapy with Peginterferon.
Copyright © 2015. Published by Elsevier B.V.


KEYWORDS: Chronic hepatitis B (CHB); Hepatitis B e antigen (HBeAg); Hepatitis B surface antigen (HBsAg); Peginterferon; Sustained virological response (SVR)

StephenW

Ĵ临床病毒学杂志。 2015年10月9日，72：88-94。 DOI：10.1016 / j.jcv.2015.09.012。 [打印EPUB提前]
定量乙肝表面抗原结合乙型肝炎e抗原在延长治疗聚乙二醇干扰素α-2a的乙肝e抗原阳性慢性乙型肝炎持续病毒学应答的预测
陈J1，张DH1，徐CR2，朱MY1，杨ZT1，龚QM1，于DM3，张XX4。
作者信息

    1Research单位临床病毒学，传染病和呼吸系统疾病研究所附属瑞金医院，上海交通大学医学院，上海200025，中华人民共和国。
    厦门大学教研室感染疾病，东南医院，漳州363000，中华人民共和国。
    3Research单位临床病毒学，传染病和呼吸系统疾病研究所附属瑞金医院，上海交通大学医学院，上海200025，中华人民共和国。电子地址：[email protected]。
    4Research单位临床病毒学，传染病研究所和呼吸杂志，瑞金医院，上海交通大学医学院，上海200025，中华人民共和国;转化医学研究中心，瑞金医院北，上海交通大学医学院，上海200025，中华人民共和国。电子地址：[email protected]。

抽象的
背景：

慢性乙型肝炎患者48周的聚乙二醇干扰素为基础的治疗反应不佳，最好的策略一直是有争议的，乙肝表面抗原的预测值（乙肝表面抗原），乙肝e抗原（HBeAg）和乙肝病毒（HBV）DNA用于确定这些患者的持续病毒学应答（SVR）的水平是不确定的。
目的：

为了优化这些患者管理和评价使用这些serobiomarkers来预测SVR。
学习规划：

81例具有不令人满意的响应48周聚乙二醇化干扰素为基础的治疗后同扩展聚乙二醇干扰素治疗有或没有核蛋白（多个）潮类似物（NAS）处理，共96个聚乙二醇干扰素个星期的治疗的。乙肝表面抗原，HBeAg和HBV DNA水平在治疗期间连续监测和随访。
结果与结论：

第二十六条的81例（32.1％）获得SVR在72周的随访。的SVR率没有接收1年延长聚乙二醇干扰素的有或没有来港组之间统计学差异。该血清HBsAg截止1800IU /毫升48周72周时有曲线下面积（AUC）的0.727，而血清HBsAg截止1500IU /毫升，再加上HBeAg消失，具有0.753 AUC预测SVR在随访。总之，聚乙二醇干扰素具有或不具有NAS进行治疗反应不理想48周聚乙二醇干扰素为基础的治疗后，延长治疗是一种很有前途的战略，以实现SVR和定量血清HBsAg的结合HBeAg消失48周与HBsAg水平的72周治疗可以预测SVR可以延长治疗聚乙二醇干扰素。

版权所有©2015年出版由Elsevier B.V.
关键词：

慢性乙型肝炎（CHB）;乙肝e抗原（HBeAg）; B型肝炎表面抗原（HBsAg）;聚乙二醇干扰素;持续病毒学应答（SVR）